Literature DB >> 14523035

Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose?

Jane E B Reusch1.   

Abstract

Glycemic control is the primary mediator of diabetic microvascular complications and also contributes to macrovascular complications. A new study (see related article beginning on page 1049) reveals a previously unrecognized association between oxidant activation of poly(ADP ribose) polymerase (PARP) and upregulation of known mediators of glycemic injury. Inhibitors of PARP may have potential therapeutic roles in the prevention of diabetic complications.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14523035      PMCID： PMC198532          DOI： 10.1172/JCI19902

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


  31 in total

1.  Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage.

Authors:  T Nishikawa; D Edelstein; X L Du; S Yamagishi; T Matsumura; Y Kaneda; M A Yorek; D Beebe; P J Oates; H P Hammes; I Giardino; M Brownlee
Journal:  Nature       Date:  2000-04-13       Impact factor: 49.962

2.  Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.

Authors:  S M Haffner; C M Alexander; T J Cook; S J Boccuzzi; T A Musliner; T R Pedersen; J Kjekshus; K Pyörälä
Journal:  Arch Intern Med       Date:  1999 Dec 13-27

3.  Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group.

Authors:  D A Greene; J C Arezzo; M B Brown
Journal:  Neurology       Date:  1999-08-11       Impact factor: 9.910

4.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

5.  Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

Authors:  M Tominaga; H Eguchi; H Manaka; K Igarashi; T Kato; A Sekikawa
Journal:  Diabetes Care       Date:  1999-06       Impact factor: 19.112

6.  New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study.

Authors:  F Ledru; P Ducimetière; S Battaglia; D Courbon; F Beverelli; L Guize; J L Guermonprez; B Diébold
Journal:  J Am Coll Cardiol       Date:  2001-05       Impact factor: 24.094

7.  Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators.

Authors:  R B Goldberg; M J Mellies; F M Sacks; L A Moyé; B V Howard; W J Howard; B R Davis; T G Cole; M A Pfeffer; E Braunwald
Journal:  Circulation       Date:  1998-12-08       Impact factor: 29.690

8.  Glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus. The Finnish studies.

Authors:  M Laakso
Journal:  Ann Intern Med       Date:  1996-01-01       Impact factor: 25.391

9.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

Authors:  K Pyŏrälä; T R Pedersen; J Kjekshus; O Faergeman; A G Olsson; G Thorgeirsson
Journal:  Diabetes Care       Date:  1997-04       Impact factor: 19.112
View more
  31 in total

Review 1.  Early diabetic neuropathy: triggers and mechanisms.

Authors:  Maxim Dobretsov; Dmitry Romanovsky; Joseph R Stimers
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

Review 2.  Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction.

Authors:  Csaba Szabo
Journal:  Br J Pharmacol       Date:  2009-02-06       Impact factor: 8.739

Review 3.  Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies.

Authors:  Pál Pacher; Irina G Obrosova; Jon G Mabley; Csaba Szabó
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

Review 4.  Glycemic extremes in youth with T1DM: the structural and functional integrity of the developing brain.

Authors:  Ana Maria Arbelaez; Katherine Semenkovich; Tamara Hershey
Journal:  Pediatr Diabetes       Date:  2013-10-14       Impact factor: 4.866

5.  Systemic alterations in the metabolome of diabetic NOD mice delineate increased oxidative stress accompanied by reduced inflammation and hypertriglyceremia.

Authors:  Johannes Fahrmann; Dmitry Grapov; Jun Yang; Bruce Hammock; Oliver Fiehn; Graeme I Bell; Manami Hara
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-04-07       Impact factor: 4.310

6.  Accurate spectroscopic calibration for noninvasive glucose monitoring by modeling the physiological glucose dynamics.

Authors:  Ishan Barman; Chae-Ryon Kong; Gajendra P Singh; Ramachandra R Dasari; Michael S Feld
Journal:  Anal Chem       Date:  2010-07-15       Impact factor: 6.986

7.  Transcriptional and post-translational modulation of myo-inositol oxygenase by high glucose and related pathobiological stresses.

Authors:  Baibaswata Nayak; Vinay K Kondeti; Ping Xie; Sun Lin; Navin Viswakarma; Kirtee Raparia; Yashpal S Kanwar
Journal:  J Biol Chem       Date:  2011-06-07       Impact factor: 5.157

8.  Associations of FPG, A1C and disease duration with protein markers of oxidative damage and antioxidative defense in type 2 diabetes and diabetic retinopathy.

Authors:  V S Reddy; P Agrawal; S Sethi; N Gupta; R Garg; H Madaan; V Kumar
Journal:  Eye (Lond)       Date:  2015-09-18       Impact factor: 3.775

9.  Glycation isotopic labeling with 13C-reducing sugars for quantitative analysis of glycated proteins in human plasma.

Authors:  Feliciano Priego-Capote; Alexander Scherl; Markus Müller; Patrice Waridel; Frédérique Lisacek; Jean-Charles Sanchez
Journal:  Mol Cell Proteomics       Date:  2009-11-06       Impact factor: 5.911

10.  Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation.

Authors:  Michael Pignone; Mark J Alberts; John A Colwell; Mary Cushman; Silvio E Inzucchi; Debabrata Mukherjee; Robert S Rosenson; Craig D Williams; Peter W Wilson; M Sue Kirkman
Journal:  Diabetes Care       Date:  2010-06       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.